AI Partnerships: Absci and AMD Collaborate to Advance AI Drug Discovery
Absci Corporation (ABSI), a leader in generative AI for drug creation, has partnered with AMD (AMD) in a strategic collaboration backed by a $20 million equity investment from AMD. The partnership leverages AMD Instinct™ accelerators and ROCm™ software to power Absci’s cutting-edge AI-driven drug discovery processes.
Absci’s advanced IgDesign1 model, the first in vitro validated inverse folding model for antibody design, will benefit from AMD’s high-performance computing capabilities. This integration enhances the speed and accuracy of de novo antibody design, aligning with Absci’s mission to create biologics faster and more efficiently.
“We’re pushing the boundaries of drug discovery with AMD’s innovative technology,” said Sean McClain, Founder & CEO of Absci. “This partnership enables us to develop next-generation antibody therapeutics with unprecedented efficiency.”
AMD CTO Mark Papermaster added, “We’re proud to partner with Absci in transforming biologic drug development through cutting-edge AI applications.”
As AI continues to evolve industries more partnerships and consolidations in the space can be expected. This week, Predictive Oncology (POAI), a peer of Absci, also known for their AI drug discovery technology, announced they will be acquired by Renovaro (RENB).
